» Articles » PMID: 27578034

Effects of VLA-1 Blockade on Experimental Inflammation in Mice

Overview
Journal Kobe J Med Sci
Specialty General Medicine
Date 2016 Sep 1
PMID 27578034
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

VLA-1 (very late antigen-1) is implicated in recruitment, retention and activation of leukocytes and its blockade has been referred as a potential target of new drug discovery to address unmet medical needs in inflammatory disease area. In the present study, we investigate the effects of an anti-murine CD49a (integrin α subunit of VLA-1) monoclonal antibody (Ha31/8) on various experimental models of inflammatory diseases in mice. Pretreatment with Ha31/8 at an intraperitoneal dose of 250 µg significantly (P<0.01) reduced arthritic symptoms and joint tissue damage in mice with type II collagen-induced arthritis. In addition, Ha31/8 at an intraperitoneal dose of 100 µg significantly (P<0.01) inhibited airway inflammatory cell infiltration induced by repeated exposure to cigarette smoke. In contrast, Ha31/8 failed to inhibit oxazolone-induced chronic dermatitis and OVA-induced airway hyperresponsiveness at an intraperitoneal dose of 100 µg. These results show that VLA-1 is involved, at least partly, in the pathogenesis of type II collagen-induced arthritis and cigarette smoke-induced airway inflammatory cell infiltration in mice, indicating the therapeutic potential of VLA-1 blockade against rheumatoid arthritis and chronic occlusive pulmonary disease.

Citing Articles

Decrypting Integrins by Mixed-Solvent Molecular Dynamics Simulations.

Ilie I, Ehrhardt C, Caflisch A, Weitz-Schmidt G J Chem Inf Model. 2023; 63(12):3878-3891.

PMID: 37310029 PMC: 10302478. DOI: 10.1021/acs.jcim.3c00480.

References
1.
Bank I, Rapman E, Shapiro R, Schiby G, Goldberg I, Barzilai A . The epidermotropic mycosis fungoides associated alpha1beta1 integrin (VLA-1, CD49a/CD29) is primarily a collagen IV receptor on malignant T cells. J Cutan Pathol. 1999; 26(2):65-71. DOI: 10.1111/j.1600-0560.1999.tb01804.x. View

2.
de Fougerolles A, Sprague A, Nickerson-Nutter C, Rennert P, Gardner H, Gotwals P . Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest. 2000; 105(6):721-9. PMC: 377459. DOI: 10.1172/JCI7911. View

3.
Cox D, Brennan M, Moran N . Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010; 9(10):804-20. DOI: 10.1038/nrd3266. View

4.
Barnes P . New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013; 12(7):543-59. DOI: 10.1038/nrd4025. View

5.
Mitra S, Schlaepfer D . Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006; 18(5):516-23. DOI: 10.1016/j.ceb.2006.08.011. View